专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

AU2008257158A1 Heteroaryl substituted thiazoles and their use as antiviral agents 未知
公开(公告)号：AU2008257158A1
公开(公告)日：2008-12-04
申请号：AU2008257158
申请日：2008-05-22
申请人： ACHILLION PHARMACEUTICALS INC
发明人： LIU CUIXIAN , LI SHOUMING , CHEN DAWEI , QUINN JESSE , ZHANG SUOMING , GADHACHANDA VENKAT , DESHPANDE MILIND , WANG XIANGZHU , PHADKE AVINASH
IPC分类号： A61K31/4436 , A61P31/12 , C07D417/04
摘要： The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R3 to R7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.

32. 发明专利

EA010017B1 ЗАМЕЩЁННЫЕ АРИЛТИОМОЧЕВИНЫ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ВИРУСОВ 未知
公开(公告)号：EA010017B1
公开(公告)日：2008-06-30
申请号：EA200600227
申请日：2004-07-08
申请人： ACHILLION PHARMACEUTICALS INC
发明人： PHADKE AVINASH , QUINN JESSE , OHKANDA JUNKO , THURKAUF ANDREW , SHEN YIPING , LIU CUIXIAN , CHEN DAWEI , LI SHOUMING , WANG XIANGZHU
IPC分类号： C07C335/14 , A61K31/17 , A61K31/44 , C07C15/00 , C07C335/16 , C07D213/54
摘要： Описываютсязамещенныеарилтиомочевиныформулы I ифармацевтическиприемлемыесолитакихсоединений, применимыев качествепротивовирусныхсредств. Некоторыезамещенныеарилтиомочевины, раскрытыев данномописании, являютсясильнымии/илиселективнымиингибиторамирепликациивирусов, вчастности, репликациивирусагепатитаС. Такжеописываютсяфармацевтическиекомпозиции, содержащиеоднуилинесколькозамещенныхарилтиомочевини одинилинесколькофармацевтическиприемлемыхносителей, эксципиентовилиразбавителей. Такиефармацевтическиекомпозициимогутсодержатьзамещеннуюарилтиомочевинукакединственноеактивноевеществоилимогутсодержатьсочетаниезамещенногопроизводногоарилтиомочевиныи одногоилинесколькихдругихфармацевтическиактивныхвеществ. ТакжеописываютсяспособылечениязараженийвирусомгепатитаС умлекопитающих.

33. 发明专利

NO20075723L 未知
公开(公告)号：NO20075723L
公开(公告)日：2008-02-05
申请号：NO20075723
申请日：2007-11-09
申请人： ACHILLION PHARMACEUTICALS INC
发明人： DESHPANDE MILIND , WANG XIANGZHU , QUINN JESSE , LI SHOUMING , LIU CUIXIAN , ZHANG SUOMING , PHADKE AVINASH , CHEN DAWEI , GADHACHANDA VENKAT
IPC分类号： A61K31/426 , A61K31/427 , A61P31/12 , C07D277/38 , C07D417/02
摘要： The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

34. 发明专利

NZ540033A Substituted aryl thioureas and related compounds; inhibitors of viral replication 未知
公开(公告)号：NZ540033A
公开(公告)日：2007-05-31
申请号：NZ54003303
申请日：2003-11-18
申请人： ACHILLION PHARMACEUTICALS INC
发明人： CHEN DAWEI , DESHPANDE MILIND , THURKAUF ANDREW , PHADKE AVINASH , WANG XIANGZHU , SHEN YIPING , LIU CUIXIAN , QUINN JESSE , OHKANDA JUNKO , LI SHOUMING
IPC分类号： A61K31/24 , A61K31/40 , A61K31/445 , A61K31/55 , C07C335/26 , C07D207/16 , C07D207/34 , C07D209/48 , C07D211/62 , C07D211/70 , C07D211/86 , C07D213/65 , C07D213/81 , C07D215/06 , C07D217/04 , C07D233/90 , C07D239/26 , C07D257/04 , C07D261/18 , C07D263/34 , C07D271/08 , C07D271/12 , C07D277/56 , C07D277/68 , C07D285/06 , C07D295/135 , C07D295/15 , C07D307/52 , C07D307/68 , C07D307/85 , C07D311/24 , C07D333/20 , C07D333/34 , C07D333/70 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04 , C07D495/04
摘要： The disclosure provides substituted aryl thioureas and related compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein the variables A1, A2, R1, R2, X, Y, and Z are as defined in the specification. The compounds of formula (I) described herein possess potent antiviral activity. The disclosure particularly provides compounds of formula (I) that are potent and/or selective inhibitors of Hepatitis C virus replication. The disclosure also relates to pharmaceutical compositions containing one or more compound of formula (I), or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The disclosure further relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating patients suffering from certain infectious diseases. These infectious diseases include viral infections, particularly HCV infections.

35. 发明专利

NO20065736L 未知
公开(公告)号：NO20065736L
公开(公告)日：2007-02-08
申请号：NO20065736
申请日：2006-12-12
申请人： ACHILLION PHARMACEUTICALS INC
发明人： DESHPANDE MILIND , CHEN DAWEI , THURKAUF ANDREW , WANG XIANGZHU , SHEN YIPING , LIU CUIXIAN , QUINN JESSE , LI SHOUMING , PHADKE AVINASH , OHKANDA JUNKO
IPC分类号： C07D211/46 , C07D249/06 , A61K31/17 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4406 , A61K31/4412 , A61K31/443 , A61K31/445 , A61K31/455 , A61K31/47 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/50 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/53 , A61K31/5375 , A61K31/5377 , A61P31/12 , C07C335/18 , C07C335/20 , C07C335/26 , C07D211/20 , C07D211/22 , C07D211/60 , C07D211/64 , C07D211/78 , C07D213/56 , C07D213/75 , C07D213/82 , C07D213/84 , C07D213/85 , C07D215/54 , C07D231/14 , C07D233/54 , C07D233/60 , C07D233/90 , C07D237/24 , C07D239/28 , C07D241/24 , C07D241/42 , C07D241/44 , C07D253/06 , C07D253/07 , C07D261/18 , C07D263/34 , C07D263/58 , C07D265/30 , C07D271/12 , C07D277/20 , C07D277/56 , C07D277/68 , C07D285/06 , C07D295/10 , C07D295/14 , C07D295/15 , C07D307/68 , C07D307/84 , C07D307/85 , C07D309/38 , C07D311/04 , C07D311/58 , C07D333/38 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D419/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D495/04 , C07D513/04
摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

36. 发明专利

AU2006244203A1 Thiazole compounds and methods of use 未知
公开(公告)号：AU2006244203A1
公开(公告)日：2006-11-16
申请号：AU2006244203
申请日：2006-05-09
申请人： ACHILLION PHARMACEUTICALS INC
发明人： GADHACHANDA VENKAT , WANG XIANGZHU , ZHANG SUOMING , PHADKE AVINASH , CHEN DAWEI , QUINN JESSE , LI SHOUMING , LIU CUIXIAN , DESHPANDE MILIND
IPC分类号： A61K31/426 , A61K31/427 , A61P31/12 , C07D277/38 , C07D277/42 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , C07D487/04 , C07D513/04
摘要： The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

37. 发明专利

OA12961A Substituted aryl thioureas and related compounds, inhibitors of viral replication. 未知
公开(公告)号：OA12961A
公开(公告)日：2006-10-13
申请号：OA1200500150
申请日：2003-11-18
申请人： ACHILLION PHARMACEUTICALS INC
发明人： CHEN DAWEI , DESHPANDE MILIND , LI SHOUMING , LIU CUIXIAN , OHKANDA JUNKO , PHADKE AVINASH , QUIN JESSE , SHEN YIPING , THURKAUF ANDREW , WANG XIANGZHU
IPC分类号： A61K31/24 , A61K31/40 , A61K31/445 , A61K31/55 , C07C335/26 , C07D207/16 , C07D207/34 , C07D209/48 , C07D211/62 , C07D211/70 , C07D211/86 , C07D213/65 , C07D213/81 , C07D215/06 , C07D217/04 , C07D233/90 , C07D239/26 , C07D257/04 , C07D261/18 , C07D263/34 , C07D271/08 , C07D271/12 , C07D277/56 , C07D277/68 , C07D285/06 , C07D295/135 , C07D295/15 , C07D307/52 , C07D307/68 , C07D307/85 , C07D311/24 , C07D333/20 , C07D333/34 , C07D333/70 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04 , C07D495/04
摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

38. 发明专利

CA2531068A1 SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OFVIRAL REPLICATION 未知
公开(公告)号：CA2531068A1
公开(公告)日：2005-01-27
申请号：CA2531068
申请日：2004-07-08
申请人： ACHILLION PHARMACEUTICALS INC
发明人： PHADKE AVINASH , QUINN JESSE , SHEN YIPING , OHKANDA JUNKO , THURKAUF ANDREW , LIU CUIXIAN , CHEN DAWEI , LI SHOUMING
IPC分类号： C07C335/14 , A61K31/17 , A61K31/44 , C07C15/00 , C07C335/16 , C07D213/54
摘要： Substituted arylthiourea compounds of Formula I, and the pharmaceutically acceptable salts of such compounds, useful as antiviral agents, are provided herein. Certain substituted arylthioureas disclosed herein are potent and/ o r selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions containing one or more substituted arylthiourea compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Such pharmaceutical composition s may contain a substituted arylthiourea as the only active agent or may conta in a combination of a substituted arylthiourea derivative and one or more other pharmaceutically active agents. Methods of treating Hepatitis C viral infections in mammals are also provided herein.

39. 发明专利

EA022134B1 4-АМИНО-4-ОКСОБУТАНОИЛ-ПЕПТИДЫ КАК ИНГИБИТОРЫ РЕПЛИКАЦИИ ВИРУСОВ 未知
公开(公告)号：EA022134B1
公开(公告)日：2015-11-30
申请号：EA201100928
申请日：2009-12-10
申请人： ACHILLION PHARMACEUTICALS INC
发明人： PHADKE AVINASH , CHEN DAWEI , GADHACHANDA VENKAT , HASHIMOTO AKIHIRO , PAIS GODWIN , WANG XIANGZHU , AGARWAL ATUL , KIM HA YOUNG , LI SHOUMING , LIU CUIXIAN , ZHANG SUOMING , DESHPANDE MILIND
IPC分类号： C07D403/14 , A61K31/437 , A61P31/12 , C07D413/14
摘要： Изобретениепредоставляет 4-амино-4-оксобутаноил-пептидыформулы Iифармацевтическиприемлемыесолии гидратысоединения. Переменные R-R, R, R, R, M, n, T, Y и Z определеныв описании. Некоторыесоединенияформулы I являютсяпригоднымив качествепротивовирусныхсредств. 4-Амино-4-оксобутаноил-пептиды, раскрытыев описании, являютсяэффективнымии/илиселективнымиингибиторамирепликациивирусов, вчастностирепликациивирусагепатитаС. Изобретениетакжепредоставляетфармацевтическиекомпозиции, содержащиеодинилиболее 4-амино-4-оксобутаноил-пептидови одинилиболеефармацевтическиприемлемыхносителей. Такиефармацевтическиекомпозициимогутсодержать 4-амино-4-оксобутаноил-пептидыкакединственноеактивноевеществоилимогутсодержатькомбинацию 4-амино-4-оксобутаноил-пептидови одногоилиболеедругихфармацевтическиактивныхвеществ. Изобретениетакжепредоставляетспособылечениявирусныхинфекций, включаяинфекциивирусомгепатитаС.

40. 发明专利

EA021794B1 ЦИКЛИЧЕСКИЕ АНАЛОГИ 4-АМИНО-4-ОКСОБУТАНОИЛ ПЕПТИДОВ, ИНГИБИТОРЫ РЕПЛИКАЦИИ ВИРУСОВ 未知
公开(公告)号：EA021794B1
公开(公告)日：2015-09-30
申请号：EA201100927
申请日：2009-12-10
申请人： ACHILLION PHARMACEUTICALS INC
发明人： PHADKE AVINASH , WANG XIANGZHU , PAIS GODWIN , HASHIMOTO AKIHIRO , GADHACHANDA VENKAT , CHEN DAWEI , AGARWAL ATUL , XHANG SUOMING , LIU CUIXIAN , LI SHOUMING , DESHPANDE MILIND
IPC分类号： C07D403/14 , C07D403/12 , C07D417/14
摘要： Изобретениепредоставляет 4-амино-4-оксобутаноилпептидыи ихциклическиеаналогиформулы Iиихфармацевтическиприемлемыесоли. Переменныеопределяютсяв описании. Некоторыесоединенияформулы I являютсяпригоднымив качествепротивовирусныхсредств. Такиециклическиеаналоги 4-амино-4-оксобутаноилпептидов, какраскрытыев описании, являютсяэффективнымии/илиселективнымиингибиторамирепликациивирусов, вчастностирепликациивирусагепатитаС. Изобретениетакжепредоставляетфармацевтическиекомпозиции, содержащиеодинилиболеециклическиханалогов 4-амино-4-оксобутаноилпептидови одинилиболеефармацевтическиприемлемыхносителей. Такиефармацевтическиекомпозициимогутсодержатьциклическийаналог 4-амино-4-оксобутаноилпептидовкакединственноеактивноевеществоилимогутсодержатькомбинациюциклическогоаналога 4-амино-4-оксобутаноилпептидови одногоилиболеедругихфармацевтическиактивныхвеществ. Изобретениетакжепредоставляетспособылечениявирусныхинфекцийу пациентов, включаяинфекциивирусомгепатитаС.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式